# Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma

> **NCT03567135** · — · UNKNOWN · sponsor: **Fuzhou General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Temozolomide（TMZ）

## Key facts

- **NCT ID:** NCT03567135
- **Lead sponsor:** Fuzhou General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-01
- **Primary completion:** 2019-04-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03567135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03567135, "Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03567135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*